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Abstract
Epigenetic control participates in processes crucial in
mammalian development, such as X-chromosome in-
activation, gene imprinting, and cell type–specific gene
expression. We provide evidence that the p53-inducible
gene 14-3-3s is a new example of a gene important to
human cancer, where epigenetic mechanisms partici-
pate in the control of normal cell type–specific expres-
sion, as well as aberrant gene silencing in cancer cells.
Like a previously identified cell type–specific gene
maspin, 14-3-3s is a p53-inducible gene; however, it par-
ticipates in G2/M arrest in response to DNA-damaging
agents. 14-3-3s expression is restricted to certain epi-
thelial cell types, including breast and prostate, whereas
expression is absent in nonepithelial tissues such as
fibroblasts and lymphocytes. In this report, we show
that in normal cells expressing 14-3-3s, the 14-3-3s CpG
island is unmethylated; associated with acetylated
histones, unmethylated histone H3 lysine 9; and an ac-
cessible chromatin structure. By contrast, normal cells
that do not express 14-3-3s have a methylated 14-3-3s
CpG island with hypoacetylated histones, methylated
histone H3 lysine 9, and an inaccessible chromatin struc-
ture. These findings extend the spectrum of cell type–
specific genes controlled partly by normal epigenetic
mechanisms, and suggest that this subset of genes may
represent important targets of epigenetic dysregulation
in human cancer.
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Introduction
Mammalian cells possess the capacity to epigenetically
modify cytosine nucleotides within their DNA through cova-
lent addition of a methyl group in the context of the CpG
(cytosine–guanine) dinucleotide. Significantly, it is the only
modified base found in the genome. The significance of
cytosine methylation is important because targeted muta-
tion of DNA methyltransferase I results in embryonic
lethality [1]. However, clusters of CpG sites exist in CpG
islands [2,3]. The majority of CpG islands are located at the
5V-region of genes, often overlapping with the transcriptional
start site and the transcriptional response elements that regu-
late gene expression [2]. Generally, CpG islands in normal
tissues remain unmethylated compared to the rest of the ge-
nome; however, there are three exceptions: 1) X-chromosome
inactivation of the silenced allele, 2) silencing and mainte-
nance of imprinted genes, and 3) regulation of the expres-
sion of tissue-specific genes [4–6].
DNA methylation of CpG cytosines is a fundamental event
that follows DNA replication, which preserves DNA methylation
patterns in normal cells; aberrations in normal DNA methyla-
tion patterns play a prominent role in human diseases. Two
general types of DNA methylation changes have been ob-
served in human diseases: inappropriate hypomethylation and
hypermethylation of DNA [4,5,7–9]. The effects of DNA hypo-
methylation include the weakening of transcriptional repres-
sion in normally silenced genes, such as imprinted genes,
genes on the inactive X-chromosome, and loss of epigenetic
regulation of autosomal genes such as maspin expression in
pancreas, thyroid, lung, and bladder cancers [10–19]. Genomic
hypomethylation has also been linked to genomic instability,
resulting in inappropriate chromosomal rearrangements and
the activation of mobile genomic elements [20–23].
Aberrant hypermethylation of CpG islands is involved in
the inappropriate silencing of genes, often tumor-suppressor
genes. Methylation-induced silencing of genes in cancer was
first reported in small cell lung cancer, where Baylin et al. [7]
reported the silencing of calcitonin to be due to cytosine
methylation of its promoter region. The first link between
hypermethylation and known tumor-suppressor gene silencing
was the RB (retinoblastoma) gene [24,25]. Although RB gene
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silencing is associated with gene mutations, methylation-
induced silencing of RB does occur in a subset of sporadic
and hereditary retinoblastoma. Since then, numerous genes
involved in tumorigenesis have been identified to be in-
appropriately methylated in human cancer, with tumor types
showing specific patterns of aberrant methylation [5,26,27].
The aberrant cytosine methylation of CpG islands is as-
sociated with the alteration of chromatin structure to a tran-
scription factor– inaccessible state, which participates in
the transcriptional repression of the associated gene. In-
accessible chromatin structure and DNA methylation are
also linked to a loss of acetylation of core histones in the
nucleosomes of gene promoters and CpG islands [28–33].
Additionally, methylation of lysine residues on histone H3,
in particular methylation of the ninth lysine residue of the
histone H3 tail, is associated with cytosine methylation of
CpG islands and subsequent gene silencing [31,34].
The gene 14-3-3r, also known as Stratifin or HME1, was
first identified through the screening of a normal human
mammary epithelial cell (HMEC) cDNA library [35]. Expres-
sion of 14-3-3r occurs in a cell type–restricted fashion, with
most epithelial cell types expressing 14-3-3r whereas other
cell types, such as fibroblasts, lymphocytes, and brain tis-
sues, do not express 14-3-3r. DNA-damaging agents and
g-irradiation induce 14-3-3r through activation of p53 in
epithelial cells, which then contributes to the induction of
G2 cell cycle arrest; however, the same treatment fails to in-
duce 14-3-3r in human diploid fibroblasts and human endo-
thelial cells [36]. Additionally, exogenous overexpression of
14-3-3r participates in the induction of DNA damage–induced
G2 cell cycle arrest. The ability of 14-3-3r to induce G2 arrest
is due to its ability to bind to, and sequester, the CDC2–
cyclin–B1 complex within the cytoplasm, preventing it from
initiating the transition from the G2 phase to the M phase of
cell cycle [37]. In addition to this well-documented 14-3-3r
function, its general phospho-specific binding activity indi-
cates its ability to switch the function of an epithelial-specific
integrin (a6b4) from a mechanical adhesive device to a sig-
naling component [38].
Originally identified as an epithelial-specific marker
downregulated in breast cancer cell lines compared to
HMECs [35,39], it was later reported that the downregula-
tion of 14-3-3r was associated with the hypermethylation
of the 14-3-3r CpG island [40]. Since then, methylation-
induced silencing of 14-3-3r has been reported to occur in
prostate, lung, basal cell, and hepatocellular carcinomas
[41–45]. Subsequently, analysis of grossly dissected mam-
mary ducts with ductal carcinoma in situ (DCIS) [46] sug-
gested that loss of 14-3-3r was an early event in breast
tumors due to cytosine methylation of its CpG island.
In this report, we show that epigenetic mechanisms
participate in the normal cell type–specific expression of
14-3-3r. In normal 14-3-3r–positive cells, the 14-3-3r CpG
island is completely unmethylated; the associated histones
are hyperacetylated, unmethylated at histone H3 lysine
9 residues; and an accessible chromatin structure is pres-
ent. In normal 14-3-3r–negative cells, the 14-3-3r CpG is-
land is completely methylated; associated H3 and H4
histones are hypoacetylated, methylated at histone H3 ly-
sine 9 residues; and an inaccessible chromatin structure is
present. Furthermore, the loss of 14-3-3r expression in
tumor cells derived from normal 14-3-3r –positive epithe-
lial tissues is associated with the recapitulation of the epi-
genetic state seen in normal 14-3-3r –negative cell types.
These results show that 14-3-3r is the newest member of
a class of cell type–specific genes regulated by epigenetic
mechanisms; extend the spectrum of cell type–specific
genes that are controlled, at least in part, by normal epi-
genetic mechanisms; and suggest that this subset of genes
may represent important targets of epigenetic dysregulation
in human cancers. In addition, these data emphasize the
importance of analyzing pure populations of cell types (tumor
or normal) to obtain the most accurate measurements of
epigenetic state.
Materials and Methods
Cell Culture and Manipulations
Normal HMECs and human prostate epithelial cells
(PrECs) were obtained from Clonetics (San Diego, CA)
and fetal skin keratinocytes were from Cell Applications
(San Diego, CA), grown according to the manufacturer’s
instructions. Human foreskin fibroblasts (HFFs) were main-
tained and cultured in the Arizona Cancer Center’s Cell
Culture Shared Service (Tuczon, AZ). Peripheral blood
lymphocytes (PBLs) were obtained from the whole blood
of healthy donors in accordance with the Health Insur-
ance Portability and Accountability Act of 1996 (HIPPA)
guidelines. Briefly, whole blood was collected into BD Vacu-
tainer CPT cell preparation tubes containing sodium heparin
(Becton Dickinson, Franklin Lakes, NJ) and processed ac-
cording to the manufacturer’s protocol. Primary cultures of
normal human oral keratinocytes (NHOKs) were established
and maintained in short-term culture as described [6,47,48].
Primary cultures of human airway epithelial cells were ob-
tained by enzymatic digestion of bronchial samples from lung
transplants and maintained in short-term culture as de-
scribed [49,50]. The BT549 breast cancer cell line and the
LnCAP prostate cancer cell lines were grown as described
[30,51]. HFFs were treated with 100 and 500 nM doxorubicin
for 18 hours, prior to RNA and protein isolation.
RNA Isolation and Reverse Transcription Polymerase
Chain Reaction (RT-PCR) Analysis of Gene Expression
Total cellular RNA was isolated using the Qiagen RNeasy
Mini kit (Qiagen, Valencia, CA); all RNA isolated were
analyzed on an Agilent Bioanalyzer RNA LabChip (Agilent
Technologies, Palo Alto, CA) to determine the quantity and
RNA integrity numbers (RINs).
RT of total RNA was performed using TaqMan Reverse
Transcription Reagents (Roche Molecular Systems, Branch-
burg, NJ) according to Applied Biosystems (ABI) protocols (Ap-
plied Biosystems, Foster City, CA). 14-3-3r, cyclin-dependent
kinase inhibitor 1A (CDKN1A or p21), mouse double minute
2 homolog (MDM2), and GAPDH-specific primer probes were
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purchased from ABI, and PCR was performed in accor-
dance with ABI protocols. Differences in expression were de-
termined using the comparative Ct method described in the
ABI user manual.
Western Blot Analysis
Total cell lysate was separated on a 15% SDS-PAGE gel
and transferred to PVDF membrane by standard methods.
An anti-p53 mouse monoclonal antibody (clone DO1; Onco-
gene Research Products, San Diego, CA) diluted to 1:1000,
followed by a 1:10,000 dilution of goat antimouse horseradish
peroxidase–conjugated antibody, was used to detect p53.
The horseradish peroxidase–conjugated antibodies were vi-
sualized by exposure of the blot to enhanced chemilumines-
cence (ECL) staining (Amersham Pharmacia Biotechnology,
Piscataway, NJ).
Sodium Bisulfite Genomic DNA (gDNA) Sequencing
One to five micrograms of gDNA was modified with
sodium bisulfite, as previously described [30]. Nested PCR
was performed with the modified DNA. Primer sequences
are available on request. The first round of PCR was
performed using 2.5 ml of modified DNA in a total reaction
volume of 25 ml following the EppendorfR MasterMix pro-
tocol (Brinkmann Instruments, Inc., Westbury, NY). PCR
conditions are as follows: 95jC for 5 minutes followed by
35 cycles of 92jC for 2 minutes, 58jC for 3 minutes, 72jC
for 2 minutes, and a final extension of 72jC for 5 minutes. In
the second round of PCR, 2.5 ml of the first-round product
was amplified as stated above, but with an annealing tem-
perature of 60jC. PCR products were cloned into the pGEM-
T-Easy vector (Promega, Madison, WI). Ten cloned PCR
products were sequenced to determine the percent methyl-
ation of the 27 CpG sites in the region analyzed.
Chromatin Immunoprecipitations (ChIPs)
ChIPs using the anti–acetyl-histone H3 and H4 anti-
bodies were performed as previously described [31]. In ad-
dition, we analyzed the histone methylation of histone H3
lysine 9, with anti–dimethyl histone H3 lysine 9 (cat no. 07-441;
Upstate Biotechnology, Waltham, MA). PCR amplification
was performed using Taqman primer/probes specific for
the CpG island of 14-3-3r. Primers were designed using the
ABI Assays by Design Service (Foster City, CA). Real-time
PCR was performed using the ABI Prism 7000 sequence
detector in accordance with ABI protocols. Quantification
was determined by applying the comparative Ct method, as
described in the ABI 7000 user guide and [30,52].
Chromatin Accessibility Assays
Chromatin accessibility assays were performed as de-
scribed with modifications [31]. Isolated whole nuclei were
subjected to MspI digest for 15 minutes and DNA was
isolated. Real-time PCR was conducted using primers de-
signed to flank five MspI sites within the 14-3-3r CpG island
(Figure 2A). Primer sequences are available on request.
Real-time PCR amplification was performed using the 2
SYBR Green PCR Master Mix according to the manufac-
turer’s protocol (ABI). PCR conditions are as follows: 5 min-
utes of denaturation at 95jC followed by 40 cycles of 95jC
for 1 minute, 59jC for 30 seconds, and 72jC for 1 minute.
Following amplification, PCR products were subjected to the
dissociation protocol as described in the ABI user manual.
Relative levels of chromatin accessibility were determined
using the comparative Ct method (described above). Real-
time PCR products were also separated on a 3% TBE
agarose gel to verify the presence of a single PCR product
of appropriate size (684 bp).
Results
Cell type–specific gene expression of 14-3-3r was con-
firmed and extended through quantitative real-time RT-
PCR analysis of a variety of normal tissues. The results in
Figure 1 show that 14-3-3r is limited to certain types of
epithelial cells including those of the airway, breast, skin,
Figure 1. 14-3-3r Expression is restricted to a subset of normal human cell types. 14-3-3r Expression was assessed by real-time quantitative RT-PCR; GAPDH
was used to normalize the expression data.
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prostate, and mouth, whereas skin fibroblasts, lymphocytes,
chondrocytes, bone marrow, heart, and kidney do not ex-
press detectable levels of 14-3-3r.
The cytosine methylation status of the GC-rich 14-3-3r
CpG island region displays a striking inverse correlation
with the expression of 14-3-3r in normal tissues (Figures 1
and 2B). The 14-3-3r CpG island [3,40] is located between
nucleotides +8 and +806, and meets the criteria of a CpG
island based on size, GC content, and CpG dinucleotide
frequency (Figure 2A). Sodium bisulfite sequencing analy-
sis of 27 CpG sites over a 475-nucleotide region shows that
the CpG sites are unmethylated in all 14-3-3r–positive tis-
sues, with the exception of a few sites of stochastic methyla-
tion, whereas the 14-3-3r CpG island is densely methylated
in all of the 14-3-3r–negative tissues analyzed (Figure 2B).
The dense methylation of the 14-3-3r CpG island seen
in normal 14-3-3r –negative tissues is similar to the methyl-
ation state recapitulated in cancer cell lines where the 14-3-3r
gene is often silenced [40,45,46]. We sequenced two tumor
cell lines, breast and prostate (BT549 and LnCAP), that have
lost 14-3-3r expression (Figure 2C). As shown in Figure 2C,
gene silencing in respective tumor types is associated with ab-
errant methylation of the 14-3-3r CpG island. Together, these
results indicate that the cell type–specific methylation pattern
of the 14-3-3r CpG island that exists in normal nonexpress-
ing cells can be recapitulated in tumorigenic cells whose nor-
mal counterparts transcribe 14-3-3r, and that this methylation
pattern is associated with its transcriptional silencing.
As a clear link between gene expression, DNA methyla-
tion state, and histone acetylation has been established,
we next sought to determine the acetylation state of the his-
tones H3 and H4, which are associated with the 14-3-3r
CpG island. 14-3-3r –positive and 14-3-3r–negative tis-
sues were analyzed in this region of differential cytosine
methylation for histone acetylation by ChIPs, using anti-
bodies specific to acetylated histones H3 and H4. The cell
type–specific differences seen in the methylation status of
the 14-3-3r CpG island are also coincident with differences
in histone acetylation. The histone acetylation status is shown
in Figure 3, and demonstrates that the 14-3-3r CpG island is
enriched for acetylated histonesH3 andH4 in unmethylated 14-
3-3r –positive HMECs and PrECs. In contrast, cytosine-
methylated 14-3-3r–negative PBLs are hypoacetylated,
whereas HFFs show a slight enrichment, but by compari-
son, it is 43-fold and 11-fold less acetylated at H3 and H4,
respectively, when compared to HMECs. In contrast to the
14-3-3r CpG island, the CpG promoter of the ubiquitously
expressed glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene was enriched for acetylated H3 and H4 in
all four tissue types analyzed, supporting a close connection
between cytosine methylation and histone deacetylation in
the tissue-specific control of cell type–specific 14-3-3r
gene expression.
Histone H3 lysine 9 methylation is an epigenetic mark
that is also associated with transcriptional repression. We
conducted ChIPs utilizing an antibody specific to dimethyl
histone H3 lysine 9 in 14-3-3r–positive HMECs and 14-3-3r–
negative HFFs. The cell type–specific differences seen in the
cytosine methylation and histone acetylation of the 14-3-3r
CpG island are also coincident with differences in histone
methylation. The histone methylation status is shown in
Figure 4, which demonstrates that the 14-3-3r CpG island
is relatively enriched for dimethyl histone H3 lysine 9 in
cytosine-methylated, hypoacetylated, 14-3-3r –negative
HFFs. HFFs show a 0.77-fold increase in dimethyl histone
H3 lysine 9 when compared to input DNA, and a 4.4-fold
increase in methylation when compared to 14-3-3r–positive
HMECs. In contrast, the 14-3-3r–positive HMECs that con-
tain an unmethylated CpG island and hyperacetylated his-
tones contain relatively hypomethylated histone H3 lysine
9 residues. As a control, we analyzed the CpG island pro-
moter of the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene, which is expressed in both HFFs and
HMECs. As shown in Figure 4, the GAPDH promoter is rela-
tively unmethylated in both HMECs andHFFs. Thus, our data
suggest a close association between cytosine methylation,
histone acetylation, and histone methylation in the control of
cell type–specific 14-3-3r gene expression.
The local differences in the epigenetic state of the 14-3-3r
CpG island in 14-3-3r –positive and 14-3-3r–negative cells
are accompanied by fundamental differences in the chroma-
tin structure of this region. A real-time PCR approach was
used to analyze the accessibility of the restriction enzyme
MspI to its cognate site in the 14-3-3r CpG island. PCR
primers were designed to flank five MspI sites within the
CpG island, shown in Figure 2A. This chromatin acces-
sibility assay is based on the idea that inaccessible regions
are not digested by the restriction enzyme and DNA-binding
protein MspI, resulting in an intact PCR template and sub-
sequently a PCR product. Conversely, accessible regions
will be digested by MspI, destroying the PCR template and
yielding quantitatively less PCR product in the real-time
PCR reaction. As such, inaccessible chromatin is seen as
a positive display of a PCR product, whereas accessible
chromatin is digested by MspI and produces less PCR
product during amplification. As controls, total intact gDNA
and in vitro MspI-digested DNA were amplified. Amplified
gDNA served as a positive control for inaccessible chroma-
tion, whereas in vitro cut DNA served as a positive control
for accessible digested chromatin regions.
Figure 2. The 14-3-3r CpG island shows differential cytosine methylation between 14-3-3r–positive and 14-3-3r–negative normal human tissue. (A) Diagram of
the 14-3-3r gene and CpG island region analyzed. CpG dinucleotide, MspI restriction sites, and primers utilized are demarcated on the diagram. (B) Summary of
5-methylcytosine levels in the 14-3-3r CpG island. Ten cloned PCR products were sequenced to determine the percent methylation of the 27 CpG sites. (C)
Tumor cells are able to recapitulate methylation-induced gene silencing analogous to normal 14-3-3r–negative cell types. RNA was isolated and subjected to
real-time PCR analysis of 14-3-3r, and bisulfite-modified DNA was sequenced for analysis of methylation.
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Figure 5 shows the comparative accessibility of the 14-3-3r
CpG island relative to uncut gDNA. Only the 14-3-3r–
positive, unmethylated, acetylated 14-3-3r CpG islands in
normal mammary and prostate epithelium are accessible
to MspI binding and digestion, whereas the 14-3-3r CpG
island in the methylated, hypoacetylated, 14-3-3r–negative
skin fibroblasts and lymphocytes are inaccessible to diges-
tion with MspI. The DCt method was used to calculate dif-
ferences in levels of PCR product and therefore chromatin
accessibility between 14-3-3r–positive and 14-3-3r–negative
cells. These results indicate that the state of cytosine methyl-
ation, histone acetylation, and histone methylation is asso-
ciated with local differences in chromatin structure that likely
regulate accessibility to DNA-binding proteins/transcription
factors. A summary of the epigenetic state of the 14-3-3r CpG
island in the various normal cell types is provided in Table 1.
Finally, we conducted experiments to determine if DNA
damage–mediated induction of 14-3-3r was also functional
in normal depigenetically silenced 14-3-3r cell types. HFFs
were treated with 100 and 500 nM doxorubicin for 18 hours,
and total RNA and protein were isolated. Western blot anal-
ysis was conducted on whole cell protein lysates to verify
that the dose of doxorubicin used was sufficient to in-
duce p53 protein expression in HFFs. As shown in Figure 6A
the doses of doxorubicin used were sufficient to induce
a dose-dependent increase in p53 protein expression. Sub-
sequently, RT-PCR was conducted to determine if the treat-
ment with doxorubicin was sufficient to increase the mRNA
expression of the p53-inducible genes 14-3-3r, cyclin-
dependent kinase inhibitor 1A (CDKN1A or p21), and
mouse double minute 2 homolog (MDM2). MDM2 and p21
are p53 response genes that were used as positive con-
trols for p53-mediated gene transactivation. As seen in
Figure 6B, in HFFs, both MDM2 and p21 are induced in a
dose-dependent fashion in response to treatment with doxo-
rubicin. In contrast, 14-3-3r is not induced to appreciable
levels in HFFs, consistent with the earlier observations of
Hermeking et al. [37]. Thus, these results suggest that
the closed chromatin state of the 14-3-3r CpG island in normal
14-3-3r–negative cells also serves to block DNA damage–
mediated gene induction. As such, epigenetic modifications
may act not only to orchestrate basal cell type–specific expres-
sion, but also to govern cell type–specific responses to
environmental stimuli.
Discussion
In this study, we show that epigenetic mechanisms are in-
volved in the transcriptional control of 14-3-3r in normal cell
types. These results provide further support of the hypothe-
sis that cell type–specific patterns of cytosine methyl-
ation participate in the control of cell type–specific gene
Figure 3. The histone acetylation state of the 14-3-3r CpG island is associated with cytosine methylation and expression status in normal human tissue.
Acetylation of histones H3 and H4 in the 14-3-3r CpG island and GAPDH promoter was analyzed using a quantitative ChIP assay coupled to real-time PCR.
Chromatin was immunoprecipitated from the normal cell types with either an acetylation-specific H3 or H4 antibody, or no antibody. Real-time PCR was performed
by utilizing primer/probe sets specific for the 14-3-3r CpG island and to the promoter region of GAPDH. HFFs, human foreskin fibroblasts; HMECs, human
mammary epithelial cells; PrECs, prostate epithelial cells; PBLs, peripheral blood lymphocytes.
Figure 4. The histone H3 dimethyl-lysine 9 methylation state of the 14-3-3r
CpG island is associated with cytosine methylation, histone acetylation, and
expression status in normal human tissues. Methylation of histone H3 lysine 9
within the 14-3-3r CpG island and GAPDH promoter was analyzed using a
quantitative ChIP assay. Chromatin was immunoprecipitated from the normal
cell types with a dimethyl histone H3 lysine 9 antibody or no antibody. Real-
time PCR was performed by utilizing primers specific for the 14-3-3r CpG
island and to the promoter region of GAPDH.
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expression and, by extension, cellular differentiation [53–55].
Confirming and extending previous works, we find that
normal 14-3-3r expression is limited to cells of epithe-
lial origin. In this study, we extend these observations to
show that the expression of 14-3-3r is associated with
a 14-3-3r CpG island that is unmethylated; has hyper-
acetylated histones, unmethylated histone lysine 9 resi-
dues; and has an open chromatin structure. In contrast,
normal cells that are 14-3-3r–negative have a methylated
14-3-3r CpG island with hypoacetylated histones H3 and H4,
methylated histone H3 lysine 9 residues, and inaccessible
chromatin structure. In addition, these epigenetic modifi-
cations cooperate to limit gene the transactivation of 14-3-3r
in response to DNA damage.
Taken together, these data indicate that epigenetic modi-
fications, such as cytosine methylation, histone acetylation,
histone methylation, and alterations in chromatin structure,
dictate cell type–specific expression of the tumor-suppressor
gene 14-3-3r. In addition to 14-3-3r, another gene that falls
into this category of epigenetically controlled genes is the
cell type–specific gene maspin [6]. Indeed, the expression
Figure 5. Chromatin structure of the 14-3-3r CpG island in positive and
negative cell types correlate with unmethylated, 14-3-3r-expressing and
methylated, 14-3-3r-nonexpressing tissue types, respectively. Intact nuclei
were digested in vivo with MspI restriction endonuclease. Following in vivo
digestion, gDNA was isolated. Real-time SYBR Green PCR was performed
using primers that flank five MspI sites. Inaccessible sites are shown by a
positive display of a PCR product, whereas accessible sites that are digested
by MspI yield fewer products following amplification. As a positive control for
PCR amplification, an equal amount of uncut gDNA was assayed; as a
negative control, an equal amount of gDNA digested with MspI was assayed.
Table 1. Summary of 14-3-3r Epigenetic State in Normal Cell Types.
Cell Type 14-3-3r
Expression*
14-3-3r CpG
Island
Methylationy
14-3-3r
Histone
Acetylationz
14-3-3r
Chromatin
Structure§
Chondrocytes  + n.d. n.d.
Bone marrow  + n.d. n.d.
Kidney  n.d. n.d. n.d.
Heart  n.d. n.d. n.d.
Skin fibroblasts  + + Closed
Lymphocytes  +  Closed
Airway epithelium +  n.d. n.d.
Prostate epithelium +  ++ Open
Mammary epithelium ++  +++ Open
Skin keratinocytes ++  n.d. n.d.
Oral keratinocytes ++++  n.d. n.d.
*RNA expression levels determined by real-time RT-PCR and relative to oral
keratinocytes ([++++] = 75–100% of oral keratinocytes; [+++] = 50–75%;
[++] = 25–50%; [+] = 1–25%; [] = <1%).
yCpG island methylation levels determined by bisulfite sequencing ([+] =
>50% methylation of total CpG sites; [] = <5% methylation of total CpG
sites; n.d. = not determined).
zHistone acetylation state determined by real-time PCR analysis of ChIPs
assay ([+++] = enriched >20-fold compared to input DNA; [++] = enriched
5- to 20-fold compared to input DNA; [+] = enriched >1- to 5-fold compared
to input DNA; [] = not enriched, <1-fold compared to input).
§Chromatin accessibility as determined by nuclease digestion in relative
terms.
Figure 6. DNA damage induction of 14-3-3r is not induced in normal
epigenetically silenced 14-3-3r cell types. (A) HFFs were treated with
doxorubicin for 18 hours prior to collection of protein whole cell lysates.
Western blot analysis for p53 was conducted. (B) HFFs were treated with
doxorubicin for 18 hours prior to collection of total RNA. Real-time
quantitative RT-PCR was conducted to analyze the expression of the p53-
inducible genes 14-3-3r, p21, and MDM2. PrECs served as an example of a
normal 14-3-3r–positive cell type.
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of both genes has been reported to be reduced or lost in
breast cancer [29,30,35,40,46]. With respect to maspin, in a
recent study, we used immunohistochemistry, laser capture
microdissection, and bisulfite sequencing to demonstrate
that aberrant methylation of the maspin promoter was asso-
ciated with loss of maspin protein expression in DCIS of
breast tissues prior to malignant transformation [56].
The results presented in this study show that, similar to
maspin, the expression of the 14-3-3r gene in normal tissue
is reflected in the epigenetic state of the 14-3-3r CpG island
in these tissues, such that normal 14-3-3r –positive and
14-3-3r–negative tissues display differences in the epige-
netic marks of CpG cytosine methylation, histone H3 and
H4 acetylation, histone H3 lysine 9 methylation, and chro-
matin structure. These results raise a cautionary note to the
results and interpretation of 14-3-3r methylation analysis in
human tumors [41–45]. Although it is likely that aberrant
methylation of the 14-3-3r CpG island is an important event
in human carcinogenesis, based on the information provided
herein, it may be advisable to revisit some of the results to
date, with greater emphasis on the detailed analysis of highly
purified tumor cell populations.
In addition to the role of epigenetic mechanisms in the
control of their normal expression and the disruption of this
mechanism in carcinogenesis, another similarity between
14-3-3r and maspin is that both are p53 target genes
[30,40,57]. Although p53 is not mutated in the normal cell
types analyzed, its ability to induce gene transactivation in
response to DNA damage is reduced in epigenetically si-
lenced 14-3-3r cell types due, in part, to the restrictive
epigenetic modifications on its CpG island, which inhibit
p53 from binding to its cognate DNA-binding domain. Inter-
estingly, epithelial tumors appear to have coopted the epi-
genotype associated with 14-3-3r–negative cell types.
Thus, as p53 function is lost in a substantial fraction of
human tumors, it follows that p53 target genes may be
downregulated, silenced, or unable to completely or properly
respond to environmental stresses or cues. Furthermore,
epithelial tumors that have lost p53 function appear to have
further adopted the epigenotype of 14-3-3r–negative cells
to mediate long-term gene silencing. This would be espe-
cially relevant to p53-dependent gene products that have
tumor-suppressor function. Together, these data suggest
to us that the loss of the transcription factor p53 may render
p53 target genes susceptible to epigenetic silencing through
aberrant DNA methylation, loss of histone H3 and H4 acety-
lation, methylation of histone H3 lysine 9, and acquisition
of an inaccessible CpG island promoter state.
The epigenetic state that is associated with gene silenc-
ing in epithelial tissue-derived tumor cells closely resembles
normal mesenchymal tissues that normally maintain these
genes in a silent and inaccessible state. As such, the ab-
errant methylation and silencing of these epithelial-specific
genes associated with the loss of p53 function may reflect
the conversion of an epithelial epigenotype to a mesenchy-
mal epigenotype, and therefore may be a manifestation of
the epithelial-to-mesenchymal transition thought to occur
during carcinogenesis.
Although the epithelial-to-mesenchymal transition is al-
most assuredly a multifaceted process, it is noteworthy that
the functions of the p53 target genesmaspin and 14-3-3r are
consistent with phenotypic changes seen during epithelial-
to-mesenchymal transition. An important function of maspin
in normal tissues is to inhibit cell motility and angiogenesis;
however, the loss of maspin in cancer, in conjunction with
changes in the epigenetic state of its CpG island promoter,
is associated with an increase in cell motility and angiogenic
activity of the affected cells. The role of 14-3-3r is more com-
plex as this epithelial-specific protein has a variety of protein-
binding partners that are important in a number of signaling
pathways governing cell proliferation, differentiation, and
apoptosis. These protein-binding partners include gluco-
corticoid receptor, insulin-like growth factor 1 receptor, phos-
photidylinositol-3-kinase, Raf-1, cdc25, and Bad [39,58,59].
The loss of 14-3-r expression through epigenetic dys-
function has wide-ranging effects that would alter cellular
responses to stimuli, and is consistent with the types of
phenotypic shifts observed in the epithelial-to-mesenchymal
transition. We suggest that epigenetic regulation through
DNA and histone modifications provides a mechanism by
which epithelial-specific genes can be turned on and off
without direct mutation to the gene itself. This epigenetic
control therefore provides for a reversible control or an epi-
genetic switch to allow for adaptation of (tumor) cells to their
environment. Indeed, althoughmaspin and 14-3-3r are often
silenced in epithelial cancers, to date, neither gene has ever
been found to be mutated or deleted in human tissues,
suggesting that this epigenetic on/off switch in normal tis-
sues is being coopted by tumor tissues for increased sur-
vival and metastatic potential.
In conclusion, we report the identification of another auto-
somal gene whose expression is controlled by epigenetic
mechanisms in normal tissues. Normal epithelial tissues are
14-3-3r–positive, and this expression is closely linked to a
14-3-3r CpG island that is unmethylated and associated
with acetylated histones H3 and H4 and unmethylated
histone H3 lysine 9, and a chromatin structure that is avail-
able for DNA–protein interaction. In contrast, normal cell
types derived from mesenchymal tissues are 14-3-3r–
negative and have a methylated 14-3-3r CpG island, under-
acetylated histones H3 and H4, methylated histone H3
lysine 9, and a chromatin structure that is not compatible
with DNA–protein interaction. This epigenotype associated
with 14-3-3r–negative mesenchymal cells can be coopted
by tumors of epithelial origin, leading to the prediction that
the epigenotype of cells can participate in epithelial-to-
mesenchymal transitions.
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